ArticleOncogene2000
Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.Molecular cancer research : MCR · 2022Article
- Review
- Article
- Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.Journal of cellular biochemistry · 2019Article
- Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.Cancer biology & therapy · 2015Article
- The transcriptional landscape of αβ T cell differentiation.Nature immunology · 2013Article
- A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.European journal of immunology · 2011Article
- Coupling of the cell cycle and apoptotic machineries in developing T cells.The Journal of biological chemistry · 2010Article
- Stem cells for skin tissue engineering and wound healing.Critical reviews in biomedical engineering · 2009Review
- Mechanisms of oncogenic cooperation in cancer initiation and metastasis.The Yale journal of biology and medicine · 2006Review
- Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.Molecular and cellular biology · 2006Article
- Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells.Molecular and cellular biology · 2005Article
- Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1.The EMBO journal · 2002Article
- Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation.Oncogene · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to study the effect of c-Myc activation in T lymphocytes in vivo, we generated transgenic mice that express a 4-hydroxytamoxifen (4-OHT)-dependent switchable c-myc oncoprotein under the control of the proximal lck promoter. Activation of c-MycER causes no obvious alteration in T cell ontogeny. However, using MHC class I restricted H-Y-TCR transgenic mice, we found that c-Myc activation in vivo enhances the efficiency of positive selection. Moreover, splenic T cells derived from lck-c-mycER transgenic mice in which c-Myc had been activated exhibited increased proliferation in vitro in response to activation with anti-CD3/CD28 antibody. Activation of c-MycER also promotes apoptosis in thymocytes in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.